GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » Days Inventory

Karyopharm Therapeutics (Karyopharm Therapeutics) Days Inventory : 188.76 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Karyopharm Therapeutics's Average Total Inventories for the three months ended in Dec. 2023 was $3.1 Mil. Karyopharm Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $1.5 Mil. Hence, Karyopharm Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 188.76.

The historical rank and industry rank for Karyopharm Therapeutics's Days Inventory or its related term are showing as below:

KPTI' s Days Inventory Range Over the Past 10 Years
Min: 52.47   Med: 268.36   Max: 362.1
Current: 263.98

During the past 13 years, Karyopharm Therapeutics's highest Days Inventory was 362.10. The lowest was 52.47. And the median was 268.36.

KPTI's Days Inventory is ranked worse than
62.1% of 649 companies
in the Biotechnology industry
Industry Median: 191.36 vs KPTI: 263.98

Karyopharm Therapeutics's Days Inventory declined from Dec. 2022 (206.95) to Dec. 2023 (188.76).

Inventory Turnover measures how fast the company turns over its inventory within a year. Karyopharm Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 was 0.48.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Karyopharm Therapeutics's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.09.


Karyopharm Therapeutics Days Inventory Historical Data

The historical data trend for Karyopharm Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Days Inventory Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.47 201.73 362.10 291.62 268.36

Karyopharm Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 206.95 271.89 286.55 339.41 188.76

Competitive Comparison of Karyopharm Therapeutics's Days Inventory

For the Biotechnology subindustry, Karyopharm Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Days Inventory falls into.



Karyopharm Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Karyopharm Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (4.224 + 3.043) / 2 ) / 4.942*365
=3.6335 / 4.942*365
=268.36

Karyopharm Therapeutics's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

Days Inventory (Q: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (3.105 + 3.043) / 2 ) / 1.486*365 / 4
=3.074 / 1.486*365 / 4
=188.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karyopharm Therapeutics  (NAS:KPTI) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Karyopharm Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Karyopharm Therapeutics's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Karyopharm Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Executives
Richard A. Paulson director, officer: President and CEO 85 WELLS AVENUE, NEWTON MA 02459
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Michael Mason officer: EVP, CFO, Treasurer 300 3RD STREET, CAMBRIDGE MA 02142
Michael Mano officer: SVP, General Counsel&Secretary 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng officer: SVP Sales & Commercial Ops C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Zhen Su director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stuart Poulton officer: EVP, Chief Development Officer 85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala officer: EVP & Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Stephen Mitchener officer: SVP, Chief Business Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Ran Frenkel officer: EVP, WW Development Operations C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah officer: EVP, Chief Medical Officer C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham officer: C.S.O & Pres. of Res & Develop C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman director, officer: President, C.E.O., C.M.O. C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037